Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.

<h4>Background</h4>Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to widespread metastatic dissemination and characterized by a desmoplastic stroma that contributes to poor outcomes. Fibroblast activation protein (FAP)-expressing Cancer-Associated Fibroblasts (CAFs) are crucial co...

Celý popis

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Aashna Karbhari, Sherly Mosessian, Kamaxi H Trivedi, Frank Valla, Mark Jacobson, Mark J Truty, Nandakumar G Patnam, Diane M Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H Kuo, Ken Herrmann, Ajit H Goenka
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2023-01-01
Edice:	PLoS ONE
On-line přístup:	https://doi.org/10.1371/journal.pone.0294564
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.

Podobné jednotky